Skip to main navigation Skip to search Skip to main content

First-in-class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: Results of a phase I dose-escalation and expansion study

  • Ryan J. Sullivan
  • , Jeffrey R. Infante
  • , Filip Janku
  • , Deborah Jean Lee Wong
  • , Jeffrey A. Sosman
  • , Vicki Keedy
  • , Manish R. Patel
  • , Geoffrey I. Shapiro
  • , James W. Mier
  • , Anthony W. Tolcher
  • , Andrea Wang-Gillam
  • , Mario Sznol
  • , Keith Flaherty
  • , Elizabeth Buchbinder
  • , Richard D. Carvajal
  • , Anna M. Varghese
  • , Mario E. Lacouture
  • , Antoni Ribas
  • , Sapna P. Patel
  • , Gary A. DeCrescenzo
    • Caroline M. Emery, Anna L. Groover, Saurabh Saha, Mary Varterasian, Dean J. Welsch, David M. Hyman, Bob T. Li

Research output: Contribution to journal › Article › peer-review

374   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'First-in-class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: Results of a phase I dose-escalation and expansion study'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science